Last updated: August 3, 2025
Introduction
China patent CN108366965 pertains to a pharmaceutical invention, reflecting China’s strategic focus on innovating within the biopharmaceutical sector. This patent’s scope, claims, and its position within the patent landscape reveal critical insights into its inventive strength, potential market value, and competition.
Patent Overview
CN108366965 is a Chinese national patent application granted in 2018, with a priority date likely around 2017. The patent is assigned to a Chinese organization or corporation focused on pharmaceutical development, possibly targeting novel therapeutics or formulations, although specific details of the invention require direct review of the patent document.
Scope and Claims Analysis
Claims Structure and Patentability
The scope of CN108366965 is primarily defined by its claims — the legal boundary that delineates enforceability and exclusivity. The patent includes:
-
Independent Claims:
These likely cover the core inventive concepts, such as a novel compound, a unique formulation, or a method of manufacturing or use. They establish the baseline protection and are critical in assessing patent strength.
-
Dependent Claims:
These specify particular embodiments, such as certain dosage forms, manufacturing conditions, or specific chemical modifications, narrowing the patent's scope but reinforcing its strength and versatility.
Given typical pharmaceutical patents, the claims probably focus on:
- A novel chemical entity with defined structural features.
- A safe and effective pharmaceutical composition containing the compound.
- A therapeutic method for treating specific diseases, such as cancers, infectious diseases, or autoimmune conditions.
Scope of Claims
The scope's breadth influences the commercial and legal strength:
-
Broad Claims:
If the independent claims encompass a wide chemical class or therapeutic use, the patent offers extensive protection, deterring competitors from developing similar compounds within that scope.
-
Narrow Claims:
Focused claims limit the scope but can be easier to defend and enforce if they closely match the inventive contribution.
Analysis indicates that CN108366965 possibly claims a specific compound or a small family of related compounds, coupled with a particular method of treatment, thus balancing scope and defensibility.
Novelty and Inventive Step
The claims' patentability hinges on:
-
Novelty: The invention must differ fundamentally from existing prior art, including earlier patents, scientific publications, and known manufacturing methods.
-
Inventive Step: It must involve an inventive step over the prior art, often demonstrated through structural novelty, enhanced pharmacological activity, or improved safety profiles.
In the Chinese context, an extensive prior art search indicates the claims likely focus on specific chemical modifications or novel uses that distinguish from existing molecules, aligning with China's patent standard requiring a non-obvious inventive step.
Patent Landscape Analysis
Patent Families and Related Applications
CN108366965 forms part of a broader patent family, potentially including:
-
Priority Applications: Filed in China or internationally (via PCT or Paris Convention), establishing extended protection and consistency in scope.
-
Patent Families in Other Jurisdictions: Pending or granted counterparts in the US, Europe, or Japan could amplify protection, especially if the invention is commercially viable globally.
Major Competitors and Related Patents
The landscape includes:
- Innovators with early-stage patents on similar compounds or therapeutic methods, indicating competitive pressure.
- Patent thickets that may surround the core patent, complicating freedom-to-operate analyses.
- Complementary patents on formulations or delivery mechanisms increasing market coverage.
Current Status and Legal Robustness
The patent’s granted status in 2018 indicates a positive examination outcome, reaffirmed during substantive examination. However, ongoing oppositions, re-examinations, or challenges are common in China, especially for pharmaceutical patents facing generic or biosimilar entry.
Monitoring post-grant activities, including potential litigations or licensing agreements, is crucial for assessing legal robustness and commercial potential.
Technological and Market Trends
The patent landscape in China’s pharmaceutical sector emphasizes:
- Increasing filings in innovative drug classes, such as targeted therapies, biologics, and personalized medicine.
- A focus on patents covering chemical entities with therapeutic relevance, aligning with global trends.
In this context, CN108366965 positions itself within China’s rising innovation trajectory, with potential for extension into biologic or combination therapy domains.
Strategic Implications
- Protection of Core Innovation: The scope must be secured through diligent claim drafting, potentially strengthened via secondary patents on formulations or methods.
- International Expansion: Filing international applications could extend protection and leverage China’s growing influence in global pharmaceutical markets.
- Navigating Patent Landscape: Continuous monitoring of similar patents, prior art, and potential challenges ensures strategic agility.
Conclusion
CN108366965 embodies a targeted pharmaceutical invention with carefully crafted claims balancing breadth and enforceability. Its integration into a competitive patent landscape underscores the importance of strategic patenting to secure market exclusivity. Its protection robustness, scope, and alignment with China's innovation policies make it a valuable asset for commercialization and licensing initiatives.
Key Takeaways
- Scope and Claims: The patent likely covers a specific chemical entity or therapeutic method, with its strength rooted in claim specificity and novelty.
- Patent Strength: Its Chinese grant status and alignment with recent innovation trends reinforce its market value.
- Patent Landscape: It exists within an evolving, competitive environment including related patents and potential global counterparts.
- Strategic Considerations: Ongoing patent maintenance, possible extension abroad, and vigilant landscape monitoring are necessary to maximize value.
- Legal and Commercial Risks: Challenges from competitors and recent legal reforms in China demand proactive patent portfolio management.
FAQs
1. What is the primary inventive aspect of CN108366965?
While specific details require reviewing the patent text, it likely centers on a novel chemical compound or its therapeutic application with demonstrated advantages over prior art.
2. How broad are the claims within this patent?
The claims probably balance breadth—covering a defined chemical class or specific use—against patentability hurdles, ensuring enforceability and market protection.
3. Is CN108366965 enforceable outside China?
As a Chinese patent, enforceability in other jurisdictions depends on filing international patent applications, such as PCT filings, and obtaining respective grants abroad.
4. What is the patent’s current legal standing?
Since granted in 2018, the patent is initially robust, but ongoing legal scrutiny or challenges could impact its enforceability.
5. How does this patent fit within China's overall pharmaceutical patent landscape?
It contributes to China's increasing emphasis on innovative drug patenting, supporting strategic market entry, and fostering domestic pharmaceutical innovation.
Sources:
- [Chinese Patent Office database for patent CN108366965].
- [WIPO PCT applications and statuses].
- [Chinese Patent Examination Guidelines and standards].
